Top > Search of International Patents > DOUBLE-STRANDED NUCLEIC ACID MOLECULE, CANCER CELL PROLIFERATION INHIBITOR AND PHARMACEUTICAL AGENT SUITABLE FOR PREVENTION OR TREATMENT OF UTERINE CANCER, BREAST CANCER AND BLADDER CANCER

DOUBLE-STRANDED NUCLEIC ACID MOLECULE, CANCER CELL PROLIFERATION INHIBITOR AND PHARMACEUTICAL AGENT SUITABLE FOR PREVENTION OR TREATMENT OF UTERINE CANCER, BREAST CANCER AND BLADDER CANCER

Foreign code F120006685
File No. S2007-0874-C0
Posted date May 24, 2012
Country WIPO
International application number 2008JP061346
International publication number WO 2008/156172
Date of international filing Jun 20, 2008
Date of international publication Dec 24, 2008
Priority data
  • P2007-162641 (Jun 20, 2007) JP
Title DOUBLE-STRANDED NUCLEIC ACID MOLECULE, CANCER CELL PROLIFERATION INHIBITOR AND PHARMACEUTICAL AGENT SUITABLE FOR PREVENTION OR TREATMENT OF UTERINE CANCER, BREAST CANCER AND BLADDER CANCER
Abstract Disclosed are: a double-stranded nucleic acid molecule such as siRNA which targets at least one of COX7RP gene and Efp gene which are estrogen-responsive genes and can inhibit the expression of the gene to thereby inhibit the proliferation of a cancer cell selected from an uterine cancer cell, a breast cancer cell and a bladder cancer cell effectively; a cancer cell proliferation inhibitor; and a pharmaceutical agent. Specifically disclosed are: a double-stranded nucleic acid molecule for inhibiting the expression of at least one of COX7RP gene and Efp gene, which comprises (a) a sense strand comprising a nucleotide sequence corresponding to any one of the target sequences depicted in SEQ ID NO:1 to SEQ ID NO:38 and (b) an antisense strand comprising a nucleotide sequence complementary to the sense strand (a); a cancer cell proliferation inhibitor for at least one of an uterine cancer cell, a breast cancer cell and a bladder cancer cell, which comprises the double-stranded nucleic acid molecule; and a therapeutic agent for at least one of uterine cancer, breast cancer and bladder cancer, which comprises the cancer cell proliferation inhibitor.
Scope of claims (In Japanese)
【請求項1】COX7RP遺伝子及びEfp遺伝子の少なくともいずれかの発現を抑制するための二本鎖核酸分子であって、(a)配列番号:1~配列番号:38のいずれかの標的配列に対応するヌクレオチド配列を有するセンス鎖と、(b)前記(a)のセンス鎖に相補的なヌクレオチド配列を有するアンチセンス鎖とを含むことを特徴とする二本鎖核酸分子。

【請求項2】センス鎖が、配列番号:1~配列番号:5、及び、配列番号:16~配列番号:21のいずれかの標的配列に対応するヌクレオチド配列を有するセンス鎖である請求項1に記載の二本鎖核酸分子。

【請求項3】センス鎖が、配列番号:1、配列番号:2、配列番号:4、配列番号:5、配列番号:16、配列番号:18、配列番号:19、配列番号:20、及び、配列番号:21のいずれかの標的配列に対応するヌクレオチド配列を有するセンス鎖である請求項2に記載の二本鎖核酸分子。

【請求項4】センス鎖が、配列番号:1、配列番号:2、及び、配列番号:16のいずれかの標的配列に対応するヌクレオチド配列を有するセンス鎖である請求項3に記載の二本鎖核酸分子。

【請求項5】センス鎖が、配列番号:2、及び、配列番号:16のいずれかの標的配列に対応するヌクレオチド配列を有するセンス鎖である請求項4に記載の二本鎖核酸分子。

【請求項6】二本鎖RNA及び二本鎖RNA-DNAキメラの少なくともいずれかである請求項1から5のいずれかに記載の二本鎖核酸分子。

【請求項7】siRNA及びキメラsiRNAの少なくともいずれかである請求項6に記載の二本鎖核酸分子。

【請求項8】請求項1から7のいずれかに記載の二本鎖核酸分子をコードするヌクレオチド配列を含むことを特徴とするDNA。

【請求項9】請求項8に記載のDNAを含むことを特徴とするベクター。

【請求項10】子宮癌細胞、乳癌細胞、及び膀胱癌細胞の少なくともいずれかの増殖を抑制するための癌細胞増殖抑制剤であって、請求項1から7のいずれかに記載の二本鎖核酸分子、請求項8に記載のDNA、及び、請求項9に記載のベクターの少なくともいずれかを含むことを特徴とする癌細胞増殖抑制剤。

【請求項11】子宮癌、乳癌、及び膀胱癌の少なくともいずれかを予防乃至治療するための医薬であって、請求項10に記載の癌細胞増殖抑制剤を含むことを特徴とする医薬。
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • Saitama Medical University
  • RNAi Co., Ltd.
  • Inventor
  • INOUE, Satoshi
  • IKEDA, Kazuhiro
IPC(International Patent Classification)
Specified countries AE(UTILITY MODEL),AG,AL(UTILITY MODEL),AM(PROVISIONAL PATENT)(UTILITY MODEL),AO(UTILITY MODEL),AT(UTILITY MODEL),AU,AZ(UTILITY MODEL),BA,BB,BG(UTILITY MODEL),BH(UTILITY MODEL),BR(UTILITY MODEL),BW(UTILITY MODEL),BY(UTILITY MODEL),BZ(UTILITY MODEL),CA,CH,CN(UTILITY MODEL),CO(UTILITY MODEL),CR(UTILITY MODEL),CU(INVENTOR'S CERTIFICATE),CZ(UTILITY MODEL),DE(UTILITY MODEL),DK(UTILITY MODEL),DM(UTILITY MODEL),DO(UTILITY MODEL),DZ,EC(UTILITY MODEL),EE(UTILITY MODEL),EG(UTILITY MODEL),ES(UTILITY MODEL),FI(UTILITY MODEL),GB,GD,GE(UTILITY MODEL),GH(UTILITY CERTIFICATE),GM,GT,HN,HR(CONSENSUAL PATENT),HU(UTILITY MODEL),ID,IL,IN,IS,JP(UTILITY MODEL),KE(UTILITY MODEL),KG(UTILITY MODEL),KM,KN,KP(INVENTOR'S CERTIFICATE)(UTILITY MODEL),KR(UTILITY MODEL),KZ(PROVISIONAL PATENT)(UTILITY MODEL),LA,LC,LK,LR,LS(UTILITY MODEL),LT,LU,LY,MA,MD(UTILITY MODEL),ME(PETTY PATENT),MG,MK,MN,MW,MX(UTILITY MODEL),MY(UTILITY-INNOVATION),MZ(UTILITY MODEL),NA,NG,NI(UTILITY MODEL),NO,NZ,OM,PG,PH(UTILITY MODEL),PL(UTILITY MODEL),PT(UTILITY MODEL),RO,RS(PETTY PATENT),RU(UTILITY MODEL),SC,SD,SE,SG,SK(UTILITY MODEL),SL(UTILITY MODEL),SM,SV(UTILITY MODEL),SY,TJ(UTILITY MODEL),TM(PROVISIONAL PATENT),TN,TR(UTILITY MODEL),TT(UTILITY CERTIFICATE),TZ,UA(UTILITY MODEL),UG(UTILITY CERTIFICATE),US,UZ(UTILITY MODEL),VC(UTILITY CERTIFICATE),VN(PATENT FOR UTILITY SOLUTION),ZA,ZM,ZW,EP(AT,BE,BG,CH,CY,CZ,DE,DK,EE,ES,FI,FR,GB,GR,HR,HU,IE,IS,IT,LT,LU,LV,MC,MT,NL,NO,PL,PT,RO,SE,SI,SK,TR),OA(BF(UTILITY MODEL),BJ(UTILITY MODEL),CF(UTILITY MODEL),CG(UTILITY MODEL),CI(UTILITY MODEL),CM(UTILITY MODEL),GA(UTILITY MODEL),GN(UTILITY MODEL),GQ(UTILITY MODEL),GW(UTILITY MODEL),ML(UTILITY MODEL),MR(UTILITY MODEL),NE(UTILITY MODEL),SN(UTILITY MODEL),TD(UTILITY MODEL),TG(UTILITY MODEL)),AP(BW(UTILITY MODEL),GH(UTILITY MODEL),GM(UTILITY MODEL),KE(UTILITY MODEL),LS(UTILITY MODEL),MW(UTILITY MODEL),MZ(UTILITY MODEL),NA(UTILITY MODEL),SD(UTILITY MODEL),SL(UTILITY MODEL),SZ(UTILITY MODEL),TZ(UTILITY MODEL),UG(UTILITY MODEL),ZM(UTILITY MODEL),ZW(UTILITY MODEL)),EA(AM,AZ,BY,KG,KZ,MD,RU,TJ,TM)

PAGE TOP

close
close
close
close
close
close